Analysis of Screen-detected Lung Cancers' Genomic Traits

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04204499

Acronym

ASCENT

Enrollment

526

Registered

2019-12-19

Start date

2020-08-10

Completion date

2026-07-31

Last updated

2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Genomic signatures, Screen-detected cancer, Non-invasive biological and radiological parameters

Brief summary

Prospective, observational cohort study of patients undergoing surgical resection for low dose CT (LDCT) screen-detected lung cancer (detected through the SUMMIT study- ClinicalTrials.gov Identifier: NCT03934866/ lung screening programmes), in which translational research is a fundamental aspect.

Detailed description

The ASCENT study seeks to examine the genomic signatures of screen-detected cancers, in order to categorise the biological behaviour of such lesions and correlate this against non-invasive biological and radiological parameters. From these data, the plan is to explore strategies to characterise LDCT-detected cancers through non-invasive means, which the researchers believe may prove key in mitigating potential screening-associated harms.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

50 Years to 77 Years

Healthy volunteers

Inclusion criteria

1. Diagnosed with confirmed lung cancer or probable lung cancer via LDCT screening. 2. Planned for, or completed primary surgical resection either for histologically confirmed lung cancer, or strongly suspected lung cancer. 3. Able to provide written informed consent (or verbal informed consent for participants consenting to retrospective diagnostic samples and data collection only).

Exclusion criteria

1. Treatment with neoadjuvant therapy for current lung malignancy as per local MDT treatment decision. 2. Known Active Human Immunodeficiency Virus (HIV), Hepatitis B virus, Hepatitis C Virus or Syphilis.

Design outcomes

Primary

Measure	Time frame	Description
Genomic exploratory research	4 years	Measuring the differences in chromosomal instability between fast- and slow-growing screen detected cancers, quantified by weighted genome integrity index (WGII) derived from whole exome sequencing (WES) data

Countries

United Kingdom

Contacts

PRINCIPAL_INVESTIGATORSam Janes

UCL

Outcome results